Premium
PMSF, SFN, and Metformin Reduce Alpha‐synuclein Aggregation in a Yeast Model of Parkinson’s Disease
Author(s) -
Kozub Noah Joseph,
Van Brysgel Taylor,
Yerxa Christopher Anthony,
Moss Stephen,
Haak Victoria Melina,
Austriaco Nicanor
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.05854
Subject(s) - pmsf , metformin , lewy body , chemistry , parkinson's disease , medicine , disease , endocrinology , biochemistry , diabetes mellitus , enzyme
Parkinson’s Disease (PD) is the second most common neurodegenerative disease in humans. PD is marked by Lewy body formation in the brain, which disturbs the dopamine transfer system across neurons. Previous studies have shown that the protein, α‐synuclein, is a major contributor in the formation of Lewy bodies. In this study, we modeled α‐synuclein aggregation in the budding yeast, Saccharomyces cerevisiae. Using this model, we treated cells, in separate trials, with phenylmethylsulfonyl fluoride (PMSF), sulforaphane (SFN), metformin, and methylene blue (MB). Our data suggests that a 4mM concentration of PMSF, 200μg/ml of SFN, and 50mM of metformin significantly reduce protein aggregation. Different concentrations of MB had no effect on α‐synuclein aggregation. Support or Funding Information Our laboratory is supported by NIH Grant NIGMS R15 GM110578 awarded to N. Austriaco and P20GM103430 awarded to the RI ‐ INBRE Program for SURF training